



## **Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference**

November 18, 2021

BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world's foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4<sup>th</sup> Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company's website at [www.entradatx.com](http://www.entradatx.com), or by [clicking here](#). A replay will be available on the Entrada website for 90 days following the event.

### **About Entrada Therapeutics**

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

### **Entrada/Investor Contact**

Karla MacDonald  
VP, Corporate Communications  
[kmacdonald@entradatx.com](mailto:kmacdonald@entradatx.com)

### **Media Contact**

Aulani Capuchin  
Real Chemistry  
[acapuchin@realchemistry.com](mailto:acapuchin@realchemistry.com)  
(559) 355-2673